NCT01254682 is a NA clinical trial of Ostenil in Arthroscopic Surgery, sponsored by TRB Chemedica AG.

Who is sponsoring NCT01254682?

NCT01254682 is sponsored by TRB Chemedica AG.

What drugs are being tested in NCT01254682?

Interventions in NCT01254682: Ostenil, Standard arthroscopic procedure.

What condition does NCT01254682 study?

NCT01254682 studies Arthroscopic Surgery.

Is NCT01254682 still recruiting?

NCT01254682 is currently completed. Last updated 27 September 2011.

Last reviewed 2011-09-27 · How we verify

NCT01254682

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra-articular Hyaluronan Substitution in Arthroscopy of the Wrist

Completed NA Last updated 27 September 2011

What this trial tests

NA trial testing Ostenil in Arthroscopic Surgery in 140 participants. Completed in 1 August 2009.

Timeline

1 January 2007

Primary endpoint
1 August 2009

1 August 2009

Quick facts

Lead sponsor	TRB Chemedica AG
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	1 January 2007
Primary completion	1 August 2009
Estimated completion	1 August 2009
Sites	1 location across Germany

Drugs / interventions tested

Ostenil
Standard arthroscopic procedure

Conditions studied

Arthroscopic Surgery — all drugs for Arthroscopic Surgery →

Sponsor

TRB Chemedica AG

Who can join

Adults 18 to 80, any sex, with Arthroscopic Surgery. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Inter-group comparison of Mayo total wrist score in subjects with or without post-arthroscopic hyaluronan treatment 3 months after arthroscopic surgery.
Time frame: Baseline and 3 months
Mayo wrist score evaluation consisting of 4 sections: * Maximal grip strength on injured side (compared to maximal strength of contralateral side, measured by 4-point scale, ranking from '0' for minimal to '30' for maximal strength) * Range of motion (measured by 4-point scale, ranking from '0' for minimal to '20' for maximal mobility) * Pain (measured by 4-point scale, ranking from '0' for maxim

Sponsor's own description

The primary objective of this study is to evaluate the efficacy and safety of Ostenil application (1% hyaluronan) after arthroscopy of the wrist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other TRB Chemedica AG trials

Trials by the same sponsor.

NCT04757051 — Real-life Use of BENART TM in Patients With Symptomatic Knee Osteoarthritis · completed
NCT03879434 — Routine Application of Ostenil® Mini in Patients with Rhizarthrosis · completed
NCT03809962 — Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis · completed
NCT03734315 — Routine Application of Ostenil® in Patients with Gonarthrosis · completed
NCT03494140 — Viscontour® Serum Med in Hydration of Facial Skin · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01254682 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TRB Chemedica AG
Last refreshed: 27 September 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01254682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing